DNK333

DRUG2 trials

Sponsors

Novartis

Conditions

Irritable Bowel SyndromeIrritable Bowel Syndrome With Diarrhea (IBS-D)

Phase 2

Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

CompletedNCT00394173

NovartisIrritable Bowel Syndrome With Diarrhea (IBS-D)

Start: 2006-09-30End: 2007-10-31Updated: 2017-02-27

Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

CompletedNCT00699166

NovartisIrritable Bowel Syndrome

Start: 2004-04-30End: 2005-09-30Updated: 2008-06-17